Abstract
The tumorigenesis of intrahepatic cholangiocarcinoma (ICC) has been identified to be exceptionally involved in dysregulated Hippo/Yes-associated protein (YAP) signaling pathway (Hippo/YAP). Hippo/YAP functions as a master regulator engaged in a plethora of physiological and oncogenic processes as well. Therefore, the aberrant Hippo/YAP could serve as an Achilles' heel regarding the molecular therapeutic avenues for ICC patients. Herein, we comprehensively review the recent studies about the underlying mechanism of disrupted Hippo/YAP in ICC, how diagnostic values could be utilized upon the critical genes in this pathway, and what opportunities could be given upon this target pathway.
Keywords:
Hippo/YAP; Hippo/Yes‐associated protein; diagnosis; intrahepatic cholangiocarcinoma; therapy.
© 2024 Wiley Periodicals LLC.
MeSH terms
-
Adaptor Proteins, Signal Transducing / genetics
-
Adaptor Proteins, Signal Transducing / metabolism
-
Animals
-
Bile Duct Neoplasms* / drug therapy
-
Bile Duct Neoplasms* / genetics
-
Bile Duct Neoplasms* / metabolism
-
Bile Duct Neoplasms* / pathology
-
Cholangiocarcinoma* / drug therapy
-
Cholangiocarcinoma* / genetics
-
Cholangiocarcinoma* / metabolism
-
Cholangiocarcinoma* / pathology
-
Gene Expression Regulation, Neoplastic
-
Hippo Signaling Pathway*
-
Humans
-
Molecular Targeted Therapy / methods
-
Protein Serine-Threonine Kinases* / genetics
-
Protein Serine-Threonine Kinases* / metabolism
-
Signal Transduction*
-
Transcription Factors* / genetics
-
Transcription Factors* / metabolism
-
YAP-Signaling Proteins* / metabolism
Substances
-
Protein Serine-Threonine Kinases
-
Transcription Factors
-
YAP-Signaling Proteins
-
YAP1 protein, human
-
Adaptor Proteins, Signal Transducing